Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter retrospective study of bevacizumab combination therapy in colorectal cancer
ChiCTR2400083462Phase 4Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bevacizumab in colorectal cancer (CRC), sponsored by Henan Cancer Hospital. Primary endpoint: Incidence of adverse reactions and adverse events. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
bevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2400083462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083462.